Author
Home > Health > What is the Difference Between Interferon Beta-1A and 1B?

Guilherme Mazui

•4 minutes to read

What is the Difference Between Interferon Beta-1A and 1B?

🆚 Go to Comparative Table 🆚

Interferon beta-1a and interferon beta-1b are both used in the treatment of multiple sclerosis (MS), but they have some structural and functional differences. The main differences between the two are:

  1. Glycosylation: Interferon beta-1a is glycosylated, meaning it has a sugar molecule attached to it, while interferon beta-1b is not. This difference in glycosylation affects the biological activity of the interferons.
  2. Biological Activity: Interferon beta-1a is approximately 10 times more active than interferon beta-1b in a standard antiviral assay. The greater biological activity of IFN-beta-1a is attributed to its glycosylation.
  3. Treatment Efficacy: Some studies have shown that interferon beta-1b therapy every other day is more effective than weekly interferon beta-1a therapy in treating multiple sclerosis. However, other studies have shown that the difference between the two treatments always favored interferon beta-1b when patients were stratified according to baseline proton density.

In summary, the main differences between interferon beta-1a and beta-1b lie in their glycosylation, biological activity, and treatment efficacy. These differences may impact the choice of treatment for multiple sclerosis patients, depending on individual factors and the specific treatment regimen being used.

On this page
  • What is the Difference Between Interferon Beta-1A and 1B?
  • Comparative Table: Interferon Beta-1A vs 1B

    • Comparative Table: Interferon Beta-1A vs 1B

    Interferon beta-1a (IFN-β 1-a) and Interferon beta-1b (IFN-β 1-b) are both types of interferons used in the treatment of multiple sclerosis (MS). Here is a table comparing the differences between Interferon Beta-1a and Interferon Beta-1b:

    Parameter Interferon Beta-1a Interferon Beta-1b
    Formulation Glycosylated, produced in mammalian cells (Chinese hamster ovary) using a natural human gene sequence. Available as a suspension for intramuscular injection (Avonex). Non-glycosylated, produced in E. coli. Available as a solution for subcutaneous injection (Betaseron).
    Treatment Frequency Intramuscular injection once weekly. A study showed less injection site pain with IM IFN-β 1-a compared to Betaseron.. Subcutaneous injection every other day. A study showed more injection site pain with Betaseron compared to IM IFN-β 1-a..
    Clinical Superiority Clinical studies indicate that IFN-β 1b at the dose of 8 million international units (MIU) was superior to 1.8 MIU of IFN-β 1a on both clinical and MRI endpoints. Patient adherence to treatment is higher with intramuscular IFN-β 1-a, given once weekly, than with subcutaneous formulations requiring multiple injections per week.
    Relapse Reduction Studies show a reduction in relapses with IFN-β 1a. Studies show a reduction in relapses with IFN-β 1b.
    Disability Progression IM IFN-β 1-a has a lower mean EDSS score at 15 years compared to no therapy. In an analysis of 6-month confirmed disability worsening (CDW) over 48 weeks, the proportions of SC IFN-β 1a and IM IFN-β 1a patients with disability progression did not differ (p = 0.23).

    In summary, Interferon Beta-1a is a glycosylated formulation produced in mammalian cells and administered via intramuscular injection, while Interferon Beta-1b is a non-glycosylated formulation produced in E. coli and administered via subcutaneous injection. IFN-β 1b has shown superiority to IFN-β 1a in clinical and MRI endpoints at higher doses, but patient adherence and injection site pain may vary between the two formulations.

    Read more:

    Guilherme Mazui

    Guilherme Mazui is graduated in journalism from the Federal University of Minas Gerais (UFMG) and a master's degree in Communication from the University of São Paulo (USP). In addition, he has experience in advertising writing and has worked as a content editor in several companies.